Effects of Exergames and Resistance Training

September 25, 2023 updated by: Dr Liu Tai Wa, Hong Kong Metropolitan University

Effects of the Combined Use of Exergaming and Resistance Training in Improving the Frailty of Nursing Home Residents: A Pilot Randomised Controlled Trial

Frailty is a common geriatric condition with significantly increased vulnerability to stress and susceptibility of negative health-related outcomes. Sacropenia and impaired cognitive function are two major contributors to frailty. This study aims to evaluate the effects of the combined use of exergaming and resistance training in improving the frailty of nursing home residents.

Study Overview

Detailed Description

Frailty is a common geriatric condition with significantly increased vulnerability to stress and susceptibility of negative health-related outcomes. The prevalence rates of frailty varies across countries, and the pooled estimates of prevalence rates of 52.3% and 40.2% of frailty and prefrailty were reported among nursing home residents respectively. Previous studies also revealed that frailty is predictive for various adverse health outcomes.

Sacropenia is a major etiologic risk factor to frailty. It refers to an age-related generalised muscle disorder featuring with loss of muscle mass and function5. Talar et al systematically reviewed and meta-analysed 25 randomised controlled trials (RCTs) using resistance training among 2,267 older people (age >65 years) with pre-sarcopenia, sarcopenia, pre-frailty or frailty. It was revealed that, compared to control, resistance training with at least 8 weeks intervention period had small to large effects in improving handgrip strength, lower-limb strength, agility, gait speed, postural stability, functional performance, fat mass and muscle [Effect size (ES) = 0.29 - 0.93, p <0.001 to = 0.007].

Cognitive impairment is another major risk factor for declined frailty status among prefrail older people. Non-frail older people are known to have better performance on cognitive status, including processing speed, executive function, attention and working memory, immediate memory and delayed memory (g = 0.320 to 0.64), than frail older people. Ample research evidence suggested that cognition predicts the incidence of frailty.

Exergaming is a fast growing research trend in gerontechnology and several commercial exergaming consoles, such as the Xbox system (including Xbox One and Xbox 360) and Nintendo Will (Wii Sports and Wii Fit), are available. Ogawa et al systematically reviewed 7 clinical trials (5 RCTs and 2 uncontrolled studies) and revealed that exergaming could improve cognitive functions, including executive function, process speed and reaction time, of older people. Moreover, a recent RCT revealed that, compared with the combined use of exercise (resistance, aerobic and balance training), a 12 week Kinect-based exergaming could better improve the global cognition [F(1, 44) = 5.277, p = 0.026] as measured by the Montreal Cognitive Assessment of community-frail older people. The Kinect-based group (n = 25) also demonstrated significant improvement in verbal (p < 0.05) and working (p < 0.05) memory post-intervention but the combined exercise group (n = 21) did not.

Given that sacropenia and impaired cognitive function are 2 major contributors to frailty; and exergaming and resistance training are effective treatments in improving the cognitive function and sacropenia of older people respectively, this study aims to evaluate the effects of the combined use of exergaming and resistance training in improving the frailty of nursing home residents.

Study Type

Interventional

Enrollment (Estimated)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Ho Man Tin, Hong Kong
        • Recruiting
        • Jockey club Institute of Health
        • Contact:
          • Liu TW, PhD
          • Phone Number: 39708714

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • living in a nursing home
  • fulfilled 1, 2 or 3 Fried Criteria of frailty
  • score ≥7 of 10 on the Chinese version of the Abbreviated Mental Test
  • able to follow the instructions of assessment and intervention

Exclusion Criteria:

  • involved in any drug or other clinical trials
  • having any additional medical conditions (such as epilepsy)
  • unable to walk independently without the use of walking aids
  • having any other conditions that will hinder the assessment and intervention (e.g.,visual/audio impairment could not be corrected by glasses/hearing aids etc).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Exergames and resistance training group
Participants will receive exergaming and resistance training programme over a period of 12 weeks
In each session, the participants will receive 40 minutes of combined use of exergaming and resistance training. The participants will practice the exergames using the gaming system Nintendo Switch (Nintendo Co., Ltd, Kyoto, Japan). The gaming software "Nintendo Switch Sports" will be adopted in which arrays of exergames are available to strengthen both the upper and lower extremity muscle and improve the balance ability of participants. The exergaming programme will consist of both upper (badminton game and tennis game) and lower (soccer game) extremity games. For week 1 and 2, the participants will first practice 1-minute warm up exercise (stretching exercises) and then the 3 exergames. For week 3 to 12, the participants will receive the same warm up exercise and exergames as if week 1 and 2 but there will be an addition of light cuff weight for resistance training.
Active Comparator: Resistance training group
Participants will receive resistance training programme over a period of 12 weeks
The resistance training programme consists of 2 parts, the upper limb and lower limb resistance exercises. For the upper limb resistance exercises, the participants will first practice 5-minute warm up of upper limb using ergometer and then undergo 2 resistance exercises, including handgrip and elbow flexion. For the lower limb exercise, the participants will also first practice 5-minute warm up of lower limb using ergometer and then undergo 3 resistance exercises, including squatting, single-leg standing and knee extension.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Muscle quantity, higher score means better muscle quantity
Time Frame: T1: baseline (before the study begins)
Will be assessed using a bioelectrical impedance measurement
T1: baseline (before the study begins)
Change from baseline muscle quantity at 6 weeks
Time Frame: T2: mid-intervention (week 6)
Will be assessed using a bioelectrical impedance measurement
T2: mid-intervention (week 6)
Muscle strength, higher score means better muscle strength
Time Frame: T1: baseline (before the study begins)
Will be assessed using a handheld dynamometer
T1: baseline (before the study begins)
Change from baseline muscle strength at 6 weeks
Time Frame: T2: mid-intervention (week 6)
Will be assessed using a handheld dynamometer
T2: mid-intervention (week 6)
Change from baseline muscle strength at 12 weeks
Time Frame: T3: post-intervention (week 12)
Will be assessed using a handheld dynamometer
T3: post-intervention (week 12)
Change from baseline muscle strength at 16 weeks
Time Frame: T4: 1 month follow up (week 16)
Will be assessed using a handheld dynamometer
T4: 1 month follow up (week 16)
Change from baseline muscle strength at 24 weeks
Time Frame: T5: 3 months follow up (week 24)
Will be assessed using a handheld dynamometer
T5: 3 months follow up (week 24)
Lower Extremity functions, higher scores mean better lower extremity functions
Time Frame: T1: baseline (before the study begins)
Will be assessed using the Short Physical Performance Battery
T1: baseline (before the study begins)
Change from baseline lower extremity functions at 6 weeks
Time Frame: T2: mid-intervention (week 6)
Will be assessed using the Short Physical Performance Battery
T2: mid-intervention (week 6)
Change from baseline lower extremity functions at 12 weeks
Time Frame: T3: post-intervention (week 12)
Will be assessed using the Short Physical Performance Battery
T3: post-intervention (week 12)
Change from baseline lower extremity functions at 16 weeks
Time Frame: T4: 1 month follow up (week 16)
Will be assessed using the Short Physical Performance Battery
T4: 1 month follow up (week 16)
Change from baseline lower extremity functions at 24 weeks
Time Frame: T5: 3 months follow up (week 24)
Will be assessed using the Short Physical Performance Battery
T5: 3 months follow up (week 24)
Change from baseline muscle quantity at 12 weeks
Time Frame: T3: post-intervention (week 12)
Will be assessed using a bioelectrical impedance measurement
T3: post-intervention (week 12)
Change from baseline muscle quantity at 16 weeks
Time Frame: T4: 1 month follow up (week 16)
Will be assssed using a bioelectrical impedance measurement
T4: 1 month follow up (week 16)
Change from baseline muscle quantity at 24 weeks
Time Frame: T5: 3 months follow up (week 24)
Will be assssed using a bioelectrical impedance measurement
T5: 3 months follow up (week 24)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cognitive function, higher score means better cognitive function
Time Frame: T1: baseline (before the study begins)
Will be assessed using the Montreal Cognitive Assessment (HK version)
T1: baseline (before the study begins)
Change from baseline cognitive function at 6 weeks
Time Frame: T2: mid-intervention (week 6)
Will be assessed using the Montreal Cognitive Assessment (HK version)
T2: mid-intervention (week 6)
Change from baseline cognitive function at 12 weeks
Time Frame: T3: post-intervention (week 12)
Will be assessed using the Montreal Cognitive Assessment (HK version)
T3: post-intervention (week 12)
Change from baseline cognitive function at 16 weeks
Time Frame: T4: 1 month follow up (week 16)
Will be assessed using the Montreal Cognitive Assessment (HK version)
T4: 1 month follow up (week 16)
Change from baseline cognitive function at 24 weeks
Time Frame: T5: 3 months follow up (week 24)
Will be assessed using the Montreal Cognitive Assessment (HK version)
T5: 3 months follow up (week 24)
Mobility, longer time means worse funcitonal mobility
Time Frame: T1: baseline (before the study begins)
Will be assessed using the Timed Up and Go Test
T1: baseline (before the study begins)
Change from baseline mobility at 6 weeks
Time Frame: T2: mid-intervention (week 6)
Will be assessed using the Timed Up and Go Test
T2: mid-intervention (week 6)
Change from baseline mobility at 12 weeks
Time Frame: T3: post-intervention (week 12)
Will be assessed using the Timed Up and Go Test
T3: post-intervention (week 12)
Change from baseline mobility at 16 weeks
Time Frame: T4: 1 month follow up (week 16)
Will be assessed using the Timed Up and Go Test
T4: 1 month follow up (week 16)
Change from baseline mobility at 24 weeks
Time Frame: T5: 3 months follow up (week 24)
Will be assessed using the Timed Up and Go Test
T5: 3 months follow up (week 24)
Frailty, score range 0 to 9, higher score means higher level of frailty
Time Frame: T1: baseline (before the study begins)
Will be assessed using the Chinese version of Clinical Frailty Scale (CFS-C)
T1: baseline (before the study begins)
Change from baseline frailty at 6 weeks
Time Frame: T2: mid-intervention (week 6)
Will be assessed using the Chinese version of Clinical Frailty Scale (CFS-C)
T2: mid-intervention (week 6)
Change from baseline frailty at 12 weeks
Time Frame: T3: post-intervention (week 12)
Will be assessed using the Chinese version of Clinical Frailty Scale (CFS-C)
T3: post-intervention (week 12)
Change from baseline frailty at 16 weeks
Time Frame: T4: 1 month follow up (week 16)
Will be assessed using the Chinese version of Clinical Frailty Scale (CFS-C)
T4: 1 month follow up (week 16)
Change from baseline frailty at 24 weeks
Time Frame: T5: 3 months follow up (week 24)
Will be assessed using the Chinese version of Clinical Frailty Scale (CFS-C)
T5: 3 months follow up (week 24)
Sarcopenia, score ranged from 0 to 20, lower score means lower risk
Time Frame: T1: baseline (before the study begins)
Will be assessed using the Strength, Assistance with walking, Rise from a chair, Climb stairs and (Calf) Falls(SARC-Calf)
T1: baseline (before the study begins)
Change from baseline sarcopenia at 6 weeks
Time Frame: T2: mid-intervention (week 6)
Will be assessed using the Strength, Assistance with walking, Rise from a chair, Climb stairs and (Calf) Falls (SARC-Calf)
T2: mid-intervention (week 6)
Change from baseline sarcopenia at 12 weeks
Time Frame: T3: post-intervention (week 12)
Will be assessed using the Strength, Assistance with walking, Rise from a chair, Climb stairs and (Calf) Falls(SARC-Calf)
T3: post-intervention (week 12)
Change from baseline sarcopenia at 16 weeks
Time Frame: T4: 1 month follow up (week 16)
Will be assessed using the Strength, Assistance with walking, Rise from a chair, Climb stairs and (Calf) Falls (SARC-Calf)
T4: 1 month follow up (week 16)
Change from baseline sarcopenia at 24 weeks
Time Frame: T5: 3 month follow up (week 16)
Will be assessed using the Strength, Assistance with walking, Rise from a chair, Climb stairs and (Calf) Falls (SARC-Calf)
T5: 3 month follow up (week 16)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

October 1, 2023

Primary Completion (Estimated)

June 30, 2024

Study Completion (Estimated)

December 30, 2024

Study Registration Dates

First Submitted

June 17, 2023

First Submitted That Met QC Criteria

June 17, 2023

First Posted (Actual)

June 27, 2023

Study Record Updates

Last Update Posted (Actual)

September 28, 2023

Last Update Submitted That Met QC Criteria

September 25, 2023

Last Verified

September 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Frailty_2023

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

The datasets of the study will only be available from the corresponding author on reasonable request after the findings being published in peer-reviewed journal.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Frailty

Clinical Trials on exergames and resistance training

3
Subscribe